Chaperonin Protein CCT2 Emerges as Key Driver of Aggressive Head and Neck Cancer and Cisplatin Resistance

Head and neck squamous cell carcinoma, one of the most aggressive malignancies encountered in oncology clinics worldwide, continues to claim lives at an alarming rate, largely because tumors progress rapidly, spread to distant sites, and develop resistance to cisplatin, the cornerstone chemotherapy drug used against it. Now, a team of researchers from Sun Yat-Sen University, the Guangdong Provincial Key Laboratory of Stomatology, and Guangdong Medical University has uncovered a molecular culprit that appears to sit at the heart of all three of these deadly behaviors. Writing in the journal Genes & Diseases, the scientists report that a protein called CCT2, a subunit of the chaperonin-containing TCP-1 complex, is dramatically overexpressed in head and neck squamous cell carcinoma and functions as a master regulator of tumor growth, metastatic behavior, and chemoresistance. The discovery, published under the title CCT2 enhances c-Myc stabilization to drive tumor progression and chemoresistance in head and neck squamous cell carcinoma, offers a compelling new target for therapeutic intervention in a disease that has stubbornly resisted improvements in survival over recent decades.

The investigation began with a rigorous bioinformatic sweep of publicly available genomic data. The researchers mined The Cancer Genome Atlas HNSC dataset alongside four independent Gene Expression Omnibus datasets, namely GSE127165, GSE10121, GSE37991, and GSE30784, to identify genes consistently upregulated in tumor tissues compared with adjacent normal tissues. This cross-cohort analysis flagged 311 genes elevated in HNSCC, and among them, CCT2 stood out. Subsequent univariate Cox regression analysis across the GSE41613 and GSE42743 datasets narrowed the field to 45 common prognosis-associated genes, and CCT2 again emerged as a standout signal. Across all datasets examined, high CCT2 expression predicted poor prognosis, advanced clinical stage, and more aggressive tumor characteristics, painting a consistent statistical portrait of a gene that tracks with the worst outcomes in this disease.

Bioinformatics alone, however, can only suggest; the team turned to human tissue and laboratory models to confirm the biology. Immunohistochemistry performed on patient samples revealed robust CCT2 staining in tumor tissue relative to normal epithelium, and the same sections showed elevated Ki-67, a canonical marker of cellular proliferation, hinting that CCT2-expressing tumors were actively dividing. Western blotting on paired tumor and adjacent normal tissues from patient samples confirmed the protein-level overexpression, and the pattern held in cell culture: HNSCC cell lines including HSC-3, CAL-27, and SAS expressed far more CCT2 than normal epithelial cell lines such as HOEC and HIEC6. With the overexpression established at the transcript, protein, and tissue levels, the researchers moved to the critical question of causation.

The answer came from loss-of-function experiments that were strikingly decisive. When the researchers depleted CCT2 using knockdown techniques, HNSCC cells lost their ability to proliferate efficiently in vitro, and tumor growth slowed in vivo as well. Beyond proliferation, CCT2 depletion crippled the migratory and invasive capacities of the cancer cells, the very behaviors that enable metastasis and account for much of the lethality of head and neck cancer. Molecular profiling of these changes revealed a classic shift in epithelial-mesenchymal transition markers: the epithelial adhesion molecule E-cadherin increased, while the mesenchymal markers N-cadherin, vimentin, and Slug decreased. This signature indicates that CCT2 normally pushes cells toward the motile, invasive mesenchymal state, and its removal reverses that program, effectively locking tumor cells into a less aggressive identity.

Perhaps the most clinically consequential finding concerned cisplatin, the platinum-based chemotherapy that remains the backbone of treatment for advanced HNSCC despite frequent resistance. The researchers observed a positive correlation between CCT2 expression and cisplatin IC50 values across HNSCC cell lines, meaning that cells with more CCT2 required higher doses of the drug to die. When CCT2 was knocked down, cisplatin sensitivity rose both in cultured cells and in living tumor models, demonstrating that the effect is not an artifact of cell culture. This result positions CCT2 as a cell-intrinsic mediator of chemoresistance, offering a mechanistic explanation for why some head and neck tumors shrug off a drug that should, in principle, destroy them.

To understand how a protein chaperone subunit could exert such sweeping influence, the team dug into the signaling pathways enriched in CCT2-high tumors and found a strong signature of MYC-related activity. Co-immunoprecipitation experiments then demonstrated a direct physical interaction between CCT2 and c-Myc, the infamous transcription factor and oncogenic driver whose overexpression fuels growth in a wide range of cancers. The interaction proved functionally meaningful: cycloheximide-chase experiments, which track protein decay over time after blocking new protein synthesis, showed that CCT2 knockdown reduced c-Myc stability and shortened its half-life. In other words, CCT2 acts as a molecular bodyguard for c-Myc, protecting the oncoprotein from degradation and allowing it to accumulate to pathological levels inside tumor cells.

Downstream of this stabilization, CCT2’s influence on the cell cycle became apparent. The researchers found that CCT2 affected key cell-cycle regulators, including cyclin D1, encoded by CCND1, and cyclin E1, encoded by CCNE1, both of which drive the transitions that propel cells through division. To establish c-Myc as the functional mediator of CCT2’s effects, the team performed rescue experiments: when they overexpressed c-Myc in CCT2-deficient cells, cell-cycle progression was restored and the impaired migration and invasion were partially rescued. Conversely, knocking down c-Myc increased cisplatin sensitivity, mirroring the effect of CCT2 depletion itself. Together, these experiments sketch a coherent pathway in which CCT2 stabilizes c-Myc, which in turn orchestrates the cell-cycle programs and aggressive behaviors that define advanced HNSCC.

The study then uncovered an even more unsettling dimension of CCT2 biology, one that extends beyond individual cells to entire tumor populations. The researchers identified apoptotic vesicles, or apoVs, as vehicles for transferring chemoresistance between neighboring tumor cells. ApoVs released from cisplatin-treated HNSCC cells were found to contain CCT2, and recipient tumor cells internalized these vesicles. Once inside, the CCT2 cargo raised both CCT2 and c-Myc levels in the recipient cells, altered their cell-cycle regulators, accelerated their cell-cycle progression, and enhanced their resistance to cisplatin. Critically, vesicles derived from CCT2-depleted cells showed much weaker effects, confirming that the CCT2 payload itself was responsible for transmitting drug tolerance. This mechanism represents a form of non-genetic transfer of resistance, meaning that chemotherapy itself may inadvertently arm previously sensitive cells with the molecular machinery of survival, without any DNA mutation required.

Taken together, the findings reframe CCT2 from an obscure chaperonin subunit into a central node in the biology of head and neck squamous cell carcinoma. The protein promotes proliferation, migration, and invasion while simultaneously reducing cisplatin sensitivity through its interaction with and stabilization of c-Myc, and the apoptotic vesicle pathway adds a population-level mechanism by which resistance spreads through the tumor. For clinicians, the work suggests that CCT2 expression could serve as a biomarker for identifying patients whose tumors are likely to resist cisplatin, potentially guiding treatment intensification or alternative regimens. For drug developers, CCT2 presents an attractive therapeutic target, particularly because its effects appear to converge on a single, druggable axis involving c-Myc stabilization. As head and neck cancer continues to exact a devastating toll worldwide, strategies that disrupt the CCT2-c-Myc partnership, or that intercept the vesicle-mediated trafficking of resistance between tumor cells, could finally offer a way to blunt the rapid progression and treatment failure that have long characterized this aggressive malignancy.

Subject of Research: The role of the chaperonin subunit CCT2 in stabilizing c-Myc to drive progression and cisplatin chemoresistance in head and neck squamous cell carcinoma

Article Title: CCT2 drives HNSCC progression and cisplatin chemoresistance

Article References: CCT2 drives HNSCC progression and cisplatin chemoresistance. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: head and neck squamous cell carcinoma, CCT2, chaperonin-containing TCP-1 complex, c-Myc, cisplatin resistance, chemoresistance, epithelial-mesenchymal transition, apoptotic vesicles, cell cycle, CCND1, CCNE1, Genes & Diseases